Clues For Genetic Anticipation In Multiple Endocrine Neoplasia Type 1.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 24 02 2020
accepted: 08 05 2020
pubmed: 13 5 2020
medline: 4 2 2021
entrez: 13 5 2020
Statut: ppublish

Résumé

Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant hereditary disease caused by the loss of function of the MEN1 gene, a tumor-suppressor gene that encodes the protein menin. It is characterized by the occurrence of primary hyperparathyroidism (pHPT), duodenopancreatic neuroendocrine tumors (dpNET), pituitary tumors (PIT), adrenal adenomas, and bronchopulmonary (bp-NET), thymic, and gastric neuroendocrine tumors. More insight into factors influencing the age-related penetrance of MEN1 manifestations could provide clues for more personalized screening programs. To investigate whether genetic anticipation plays a role in the largest known MEN1 families in the Netherlands. All Dutch MEN1 families with ≥ 10 affected members in ≥ 2 successive generations were identified. Age at detection of the different MEN1-related manifestations were compared among generations using regression analyses adjusted for competing risks. To correct for the beneficial effect of being under surveillance, manifestations occurring during surveillance were also separately compared. A total of 152 MEN1 patients from 10 families were included. A significantly decreased age at detection of pHPT, dpNET, PIT, and bp-NET was found in successive generations (P < 0.0001). Adjusted analyses led to the same results. These results suggest the presence of genetic anticipation. However, due to a risk of residual bias, the results must be interpreted with caution. After independent validation in other cohorts and further translational research investigating the molecular mechanisms explaining this phenomenon in MEN1, the results might add to future, more personalized, screening protocols and earlier screening for future generations of MEN1 patients.

Identifiants

pubmed: 32396602
pii: 5836321
doi: 10.1210/clinem/dgaa257
pii:
doi:

Substances chimiques

MEN1 protein, human 0
Proto-Oncogene Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Medard F M van den Broek (MFM)

Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

Bernadette P M van Nesselrooij (BPM)

Department of Medical Genetics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.

Carolina R C Pieterman (CRC)

Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

Annemarie A Verrijn Stuart (AA)

Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.

Annenienke C van de Ven (AC)

Department of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.

Wouter W de Herder (WW)

Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.

Olaf M Dekkers (OM)

Departments of Endocrinology and Metabolism and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

Madeleine L Drent (ML)

Department of Internal Medicine, Section of Endocrinology, Amsterdam UMC, location VU University Medical Center, Amsterdam, The Netherlands.

Bas Havekes (B)

Department of Internal Medicine, Division of Endocrinology, Maastricht University Medical Center, Maastricht, The Netherlands.

Michiel N Kerstens (MN)

Department of Endocrinology, University Medical Center Groningen, Groningen, The Netherlands.

Peter H Bisschop (PH)

Department of Endocrinology and Metabolism, Amsterdam UMC, location Academic Medical Center, Amsterdam, The Netherlands.

Gerlof D Valk (GD)

Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH